Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. They are building an atlas of cancer progression to help research hospitals and pharma test experimental drugs, and to help clinicians evaluate potential treatment options for each patient to improve outcomes. The technology is applicable across solid tumors and they are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication.